Abzena's drug-boosting animal antibodies
Proactive Investors looks at Abzena, a biotech firm that engineers antibodies from animals in order to boost the effectiveness of cancer-fighting drugs.
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 21 of 21
Abzena's expanded offering plays well with customers
"Our increased capabilities and capacity are already resulting in an excellent response from customers,” said chief executive John Burt.
Faron Pharma's cash balance healthier than anticipated
Traumakine, a treatment for acute lung injury, has fast-track status in Europe but the US wants to see more evidence
PREVIEW: Will Dechra Pharmaceuticals live up to heightened expectations?
Dechra Pharmaceuticals, housebuilders Berkeley and Barratt, Halfords, Dixons Carphone, and JD Whetherspoon are on the agenda.
Proactive news highlights: Abzena, Amur Minerals, Falcon Oil & Gas, Michelmersh and more...
Versarien funds a push into graphene-related technologies, Epistem Holdings has been renamed Genedrive and Amur Minerals PLC updates on progress at the giant Kun-Manie nickel project in Russia.
Faron and Abzena agree manufacturing deal
Clevegen is part of the new generation of drugs being developed to stimulate the body’s immune system into fighting cancers.
Proactive news round-up: Abzena, Berkeley Energia, Diamondcorp ...
A snapshot of today's small company news highlights
Faron sees broad market for cancer treatment
Clevegen is a novel cancer treatment that produces an antibody that converts the immune environment around a tumour
Faron strikes Korea licensing deal for flagship drug
The agreement with a company called Pharmbio also comes with certain undisclosed milestone payments and a one-third share of profits made on the sale of Traumakine.
Proactive news highlights: Advanced Oncotherapy, Faron Pharmaceuticals, Haydale Graphene and more
Xtract Resources sells its Manic gold project, Westminster Group receives a letter of intenet from a Middle East airport and Tern is to buy a cloud management software provider.
Faron goes on the TIET offensive against cancer with new development
The company is coupling the pre-clinical drug candidate with its newly-developed tumour immunity enabling technology, or TIET for short.
Faron Pharmaceuticals appoints medical director as clinical activity expands
Faron Pharmaceuticals Ltd has hired experienced pharma executive Matti Karvonen as its new medical director as it expands its clinical activities.
Proactive news highlights: Collagen Solutions, DiamondCorp, Westminster Group, ITM Power and more
DiamondCorp a cut above the rest, ITM Power wins a prize and Westminster group repairs will begin soon.
Faron files patent application for cancer treatment
The patents have been filed in Finland but should be rolled out globally under the Patent Co-operation Treaty.
Hopes rise for AIM drug breakthroughs
A trio of AIM companies are putting potential new drugs through phase three trials
Archive
Proactive news summary: EG solutions PLC, Sound Energy PLC and more...
Magnolia petroleum updates on new wells, Sound Energy confirms new acquisition and EG Solutions face a partner bankruptcy.
Week Ahead: Argos owner could bow out on a low
Other big names reporting this week include the Pru, G4S and Paddy Power Betfair. Among small caps, updates from Telit, Forbidden Technologies and StatPro catch they eye